LIONCO PHARMACEUTICAL GROUP CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.73 CNY | +2.16% |
|
+10.26% | -14.47% |
| Sales 2022 | 289M 39.95M 54.68M | Sales 2023 | 197M 27.18M 37.21M | Capitalization | 3.99B 551M 754M |
|---|---|---|---|---|---|
| Net income 2022 | -196M -27.07M -37.05M | Net income 2023 | -151M -20.85M -28.55M | EV / Sales 2022 | 13.1 x |
| Net cash position 2022 | 345M 47.69M 65.28M | Net cash position 2023 | 168M 23.26M 31.83M | EV / Sales 2023 | 19.4 x |
| P/E ratio 2022 |
-21.3
x | P/E ratio 2023 |
-26.3
x | Employees | 475 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 36.14% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.16% | ||
| 1 week | +10.26% | ||
| 1 month | +15.93% | ||
| 3 months | +18.84% | ||
| 6 months | -14.00% | ||
| Current year | -14.47% |
1 week
4.30
4.79
1 month
3.374.79
Current year
2.945.89
1 year
2.946.07
3 years
2.9412.00
5 years
2.9412.00
10 years
2.9421.20
| Managers | Title | Age | Since |
|---|---|---|---|
Ling Ping Tao
CEO | Chief Executive Officer | 53 | 03-12-23 |
Jun Ke Zhang
DFI | Director of Finance/CFO | 38 | 16-12-31 |
Yan Chen
BRD | Director/Board Member | 46 | 07-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zi Qiang Pan
BRD | Director/Board Member | 59 | 19-02-27 |
Ling Ping Tao
CEO | Chief Executive Officer | 53 | 03-12-23 |
Xiao Gang Tao
BRD | Director/Board Member | 48 | 15-12-13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 4.73 | +2.16% | 6,428,520 |
| 24-04-29 | 4.63 | +7.93% | 9,516,944 |
| 24-04-26 | 4.29 | -.--% | 5,107,307 |
| 24-04-25 | 4.29 | +3.37% | 6,675,261 |
End-of-day quote Shanghai S.E., April 29, 2024
More quotes
Lionco Pharmaceutical Group Co.,Ltd. is a China-based company principally engaged in the research and development, production and sales of chemical prescription medicine. The Company's products are mainly categorized in to three areas: parenteral nutrition agents, anti-infectious agents and digestive system agents. The lead product of its parenteral nutrition agents is Glutamine for injection; its anti-infectious agents include Cefodizime sodium for injection and Cefathiamidine for injection, among others; its digestive system agents include Omeprazole Sodium for injection and others. The Company operates its business in domestic market.
Sector
Pharmaceuticals
Calendar
2024-05-17
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -14.47% | 460M | |
| +19.98% | 43.48B | |
| +20.67% | 22.65B | |
| +14.56% | 14.73B | |
| +14.32% | 13.79B | |
| +44.72% | 12.04B | |
| -8.37% | 7.08B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +11.90% | 5.47B |
- Stock Market
- Equities
- 603669 Stock
